Lenalidomide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Lenalidomide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
1327
Registered trials
1570
Result records
2
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Lenalidomide can convert its Degradable Molecular Glue profile and CK1α x CRBN x IKZF1 x IKZF3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Lenalidomide (query alias: lenalidomide) |
|---|---|
| Modality / target | Degradable Molecular Glue; CK1α x CRBN x IKZF1 x IKZF3; CK1α inhibitors, CRBN modulators, IKZF1 degraders |
| Highest global status | Approved |
| Originator | Celgene Corp. |
| Active developers | Bristol-Myers Squibb Pharma EEIG, Hoffmann-La Roche, Inc., Sanofi |
The MCP disease footprint includes Large B-cell lymphoma, Marginal Zone B-Cell Lymphoma, Adult T-Cell Leukemia-Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07671287 | Phase 3 | Not yet recruiting | 399 | To determine the efficacy (MRD negativity at a level of 10-6) of Tec-DRd compared to DVRd after induction/consolidation therapy and HD melphalan and ASCT, before start of maintenance therapy in participants with TE NDMM |
| NCT07652905 | Phase 2 | Not yet recruiting | 24 | Minimal residual disease (MRD) negative rate |
| NCT07697339 | Phase 1 | Not yet recruiting | 40 | Phase Ib: Incidence and severity of adverse events |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Phase II Study of CC-5013 in Patients With Advanced Renal Cell Carcinoma (RCC)
Phase 2; n=28; evaluation: not stated. Reported fields: ORR = 3 Participants ; -; -
Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment With Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy
Phase 3; n=11; evaluation: not stated. Reported fields: Symptomatic Myeloma Progression Free-survival (PFS) Rate = 100 percentage of participants (95% Confidence Interval, NA - NA); -; -
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 6 - Belantamab Mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone in Combination
Phase 1/2; n=20; evaluation: not stated. Reported fields: DE Phase: Number of Participants With Dose Limiting Toxicities (DLTs) = 1 Participants ; DE Phase: Number of Participants With Dose Limiting Toxicities (DLTs) = 2 Participants ; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Lenalidomide addresses Large B-cell lymphoma, Marginal Zone B-Cell Lymphoma, Adult T-Cell Leukemia-Lymphoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Degradable Molecular Glue—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-06-24 | Starton, Bend team on proprietary oral sustained-release dosage form of lenalidomide | Approved | Financial terms not disclosed |
| 2010-06-27 | MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program | Approved | US$13.0M upfront |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Daratumumab.bortezomib, lenalidomide and dexamethasone for treating multiple myeloma”. The milestone feed surfaced a patent-application signal described as “Methods of treating cancer using subcutaneous dosing of mosunetuzumab as a monotherapy or in combination with lenalidomide”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
